National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

pasireotide
A synthetic long-acting cyclic peptide with somatostatin-like activity. Pasireotide activates a broad spectrum of somatostatin receptors, exhbiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. This agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:SOM230



Previous:paricalcitol, Parlodel, paroxetine hydrochloride, PARP inhibitor AZD2281, PARP-1 inhibitor AG014699
Next:patient-specific follicular lymphoma-derived anti-idiotype vaccine, Pavabid, Pavatym, Paxil, pazopanib hydrochloride

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov